


Promosso da:



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

Con il patrocinio di:



L'iniziativa è stata realizzata grazie al supporto incondizionato di:



From Legacy to Leading Edge in MPN Care and Research

Presidents:

Alessandro Lucchesi
Gerardo Musuraca

Scientific Secretariat:

Alessandro Lucchesi
Monica Poggiaspalla
Francesco Malaspina
Claudio Cerchione
Maria Benedetta Giannini
Federica Frabetti

RISE
MPN
2024

Rome

8/9 november

FH55 Grand Hotel Palatino
Via Cavour, 213/M



Rationale

Drawing on recent advancements in the field of myeloproliferative neoplasms (MPNs) and incorporating a nuanced understanding of the disease's complexity, 'RiseMPN 2024' aspires to pioneer a holistic approach to MPN management. Moving beyond traditional goals of cytoreduction and proliferation control, our focus is expanding to include the quality of life, management of complications, care intensity, and the biological evolution of the disease. This shift acknowledges the importance of addressing not just the symptoms but the broader impact of MPNs on patients' lives.

Central to this new paradigm is the exploration of previously underemphasized areas such as inflammation, disimmunity, and clonal progression. These elements play crucial roles in the pathogenesis of MPNs and offer fertile ground for the development of innovative therapeutic strategies. By delving into these aspects, 'RiseMPN 2024' aims to foster a more comprehensive understanding of MPNs, ultimately leading to groundbreaking approaches that promise not only to manage but to fundamentally transform the disease landscape.

Our ambition is to catalyze a departure from the past, championing research and clinical efforts that embrace the complexity of MPNs. This includes investigating new molecular targets and pathways that could lead to disease modification, highlighting the congress's commitment to advancing care through innovation and collaboration.

In summary, 'RiseMPN 2024' is set to be a landmark event, uniting the global scientific community in pursuit of a future where the management of MPNs is revolutionized. Through a concerted focus on cutting-edge research and patient-centered care, the congress will lay the groundwork for novel therapies that promise to significantly improve the lives of those affected by MPNs.

Faculty

AL-ALI HAIFA KATHRIN HALLE-DE
BALDUINI ALESSANDRA PAVIA
CATANI LUCIA BOLOGNA
CARUBBI FRANCESCO L'AQUILA
CATTANEO DANIELE MILANO
CERCHIONE CLAUDIO MELDOLA
CILLONI DANIELA TORINO
FERRER-MARIN FRANCISCA MURCIA-ES
FAVA CARMEN TORINO
FRABETTI FEDERICA MELDOLA
FISHER THOMAS MAGDEBURG-DE
GENTILI NICOLA MELDOLA FC
GIANNINI MARIA BENEDETTA MELDOLA
GIORDANO GIULIO CAMPOBASSO
GIRELLI DOMENICO VERONA
GORI FABIO AMSTERDAM-NDL
GREENFIELD GRAEME BELFAST-NIR
GUGLIELMELLI PAOLA FIRENZE
HASSELBALCH HANS ROSKILDE-DK
KILADJIAN JEAN-JACQUES PARIS-FR

KOMROKJI ROMI TAMPA-FL
LUCCHESI ALESSANDRO MELDOLA
MALASPINA FRANCESCO MELDOLA
MARIANI GUGLIELMO LONDON-UK
MARTINELLI GIOVANNI BOLOGNA
MASSELLI ELENA PARMA
MUSURACA GERARDO MELDOLA
NAPOLITANO MARIASANTA PALERMO
O'SULLIVAN JENNIFER OXFORD-UK
OLIVA ESTHER NATALIE REGGIO CALABRIA
PALUMBO GIUSEPPE ALBERTO M. CATANIA
PATRIARCA ANDREA NOVARA
POGGIASPALLA MONICA MELDOLA
POLVERELLI NICOLA PAVIA
PUGLIESE NOVELLA NAPOLI
ROSTI GIANANTONIO MELDOLA
ROYSTON DANIEL OXFORD-UK
SOBAS MARTA ANNA WROCLAW-PL
TANTRAVAHIS SRINIVAS SALT LAKE CITY-UT
TIRIBELLI MARIO UDINE



12:30 Welcome and registration
13:15 **Lunch**
14:15 Opening (*A. Lucchesi, G. Musuraca*)

 SESSION 1: GENETICS/EPIGENETICS

Genetic Frontiers: Rewriting the Code of MPNs (*Chair: E. Masselli, D. Cilloni*)
14:20 Clonal architecture and leukaemic progression of myeloproliferative neoplasms (*J. O'Sullivan*)
14:35 Epigenetics of myeloproliferative neoplasms (*G. Greenfield*)
14:50 CALRdel52 and JAK2V617F positive granulocytes: distinct inflammatory activities and implications for the pro-thrombotic risk (*T. Fischer*)
Discussion

 SESSION 2: FUNCTIONAL AND CELLULAR BIOLOGY

Cellular Crossroads: Navigating the Complex Web of Cytokines and Microenvironments in MPNs (*Chair: G. Giordano - J. O'Sullivan*)
15:20 Megakaryocytopoiesis and bone marrow microenvironment in MPNs (*A. Balduini*)
15:35 Functionally Relevant Cytokine/Receptor Axes in Myelofibrosis (*E. Masselli*)
15:50 MPNs and their “vescicular intelligence” (*L. Catani*)
Discussion

16:20 **Coffee break**

 SESSION 3: MPNS AS VASCULAR DISEASES

Unraveling Vascular Intricacies: CHIP, Inflammation, and Thrombotic Pathways in MPNs (*Chair: G. Mariani, A. Lucchesi*)
16:35 **[Lecture]** CHIP and inflammation-induced vascular risk: how to break the vicious circle (*H. Hasselbalch*)
16:55 MPNs and endothelial dysfunction (*G. Giordano*)
17:10 Tailored prophylactic measures in MPNs: balancing thrombotic and hemorrhagic risk (*M. Napolitano*)
Discussion

 SESSION 4: SPECIAL POPULATIONS AND PERSONALIZED STRATEGIES IN MPN CARE

Exploring Pathways to Holistic Care Across Life Stages and Challenges (*Chair: M. Poggiaspalla, C. Cerchione*)
17:55 MPN-AYA: Myeloproliferative neoplasms in adolescents and young adults (*M. Sobas*)
18:10 Intersecting Paths: autoimmunity in MPNs and the case of autoimmune myelofibrosis (*F. Carubbi*)
18:25 Collaborative Care in MPNs: Quality of Life and non-pharmacological interventions (*E. N. Oliva*)
18:40 Graceful Guidance: managing MPNs in pregnancy with expert tips and insights (*P. Novella*)
Discussion

19:10 **End of Day 1** - Closing Remarks

08:40 Opening (*A. Lucchesi, G. Musuraca*)

 SESSION 5: DIGITAL TECHNOLOGIES IN CHRONIC HEMATOLOGICAL DISEASES

Harnessing the Power of Digital Innovation to Transform Hematological Care (*Chair: N. Gentili, F. Malaspina*)
08:45 AI and data-driven health care in hematology (*F. Gori*)
09:05 Using AI techniques to improve the diagnosis of MPN (*D. Royston*)
Discussion

 SESSION 6: THE FOUNDATIONS FOR NEW TREATMENTS OF MPNS

Laying the Groundwork: Iron Metabolism and Disease Modification Strategies in MPNs (*Chair: H.C. Hasselbalch, M. Napolitano*)
09:35 Iron metabolism in inflammatory diseases and MPNs (*D. Girelli*)
09:50 The evolving concept of disease modification in myelofibrosis: goals, achievements, obstacles (*M. Tiribelli*)
Discussion

10:15 **Coffee break**

 SESSION 7: ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA

Advancing Personalized Care: From Genetic Insights to Therapeutic Breakthroughs in ET and PV (*Chair: G. Musuraca, D. Girelli*)
10:30 Contemporary approach to ET: role of genetic profiling and new risk scores (*F. Ferrer-Marín*)
10:45 Interferons in PV and ET: growing evidence and strategies for development and positioning (*J. J. Kiladjian*)
11:00 JAK Inhibitors in PV and ET: milestones achieved and horizons ahead (*G. A. Palumbo*)
11:15 Emerging therapies for polycythemia vera and their possible positioning in personalized strategies (*A. Lucchesi*)
Discussion

 SESSION 8: MYELOFIBROSIS 1

Pioneering Pathways: Modulating Disease Progression and Managing Complications in Myelofibrosis (*Chair: G. Martinelli, G. Palumbo*)
11:45 Current and future positioning of different JAK2 inhibitors in MF, and their switching: emphasis on Italy-approved therapies (*P. Guglielmelli*)
12:00 Managing cytopenias and fibrosis in MF: old vs novel agents (*R. Komrokji*)
12:15 Epigenetic regulators in MF: BET, LSD1, telomerase inhibitors (*H. Al-Ali*)
Discussion

12:45 **Lunch**



SESSION 9: MYELOFIBROSIS 2

Innovative Therapeutics: Exploring Cutting-edge Treatment Strategies in Myelofibrosis
(Chair: M. Tiribelli, R. Komrokji)

- 13:55 Pro-apoptotic and anti-proliferative agents in MF: MDM2 and Bcl-XL inhibitors
(A. Patriarca)
- 14:10 Targeting DNA Integrity: The Emerging Role of XPO1 and DDR Inhibitors in Myelofibrosis
(S. Tantravahi)
- 14:25 Advanced Anti-CALR immunotherapy: harnessing immune responses against mutant CALR in MPNs
(D. Cattaneo)
- 14:40 Balancing acts: preserving transplant opportunities in the era of novel therapies
(N. Polverelli)
- Discussion



FINAL SESSION: NAVIGATING NEW FRONTIERS IN MYELOPROLIFERATIVE DISORDERS

Beyond the Mainstream: Exploring Systemic Mastocytosis and Emerging Challenges in CML
(Chair: E. N. Oliva, S. Tantravahi)

- 15:00 Hypereosinophilic syndromes: diagnostic tools and therapeutic choices (D. Cilloni)
- 15:20 All about systemic mastocytosis: biological fundamentals, current and future management
(G. Martinelli)
- 15:40 "Modern" goals and failures in CML: deep responses or global health? (G. Rosti)
- 16:00 Treatment free remission in hematologic malignancies (C. Fava)
- Burning questions
- 16:30 CLOSURE OF THE EVENT (A. Lucchesi, G. Musuraca, G. Rosti, G. Martinelli)

Informazioni

Il Convegno n. **5090-428923** è stato accreditato su **AGENAS** per **100 partecipanti**.


Professione	MEDICO CHIRURGO, BIOLOGO, TECNICO SANITARIO LABORATORIO BIOMEDICO, FARMACISTA
Discipline	EMATOLOGIA; MEDICINA INTERNA; ONCOLOGIA; BIOCHIMICA CLINICA; MEDICINA TRASFUSIONALE; FARMACISTA PUBBLICO DEL SSN; FARMACISTA TERRITORIALE; FARMACISTA DI ALTRO SETTORE; BIOLOGO; TECNICO SANITARIO LABORATORIO BIOMEDICO; ISCRITTO NELL'ELENCO SPECIALE AD ESAURIMENTO; CORSO DI AGGIORNAMENTO LINEE GUIDA - PROTOCOLLI - PROCEDURE CORSO GRATUITO
Tipologia Obiettivo	

METODO D'ISCRIZIONE

Ai fini dell'ottenimento dei crediti ECM è necessario registrarsi sulla piattaforma:
<https://didattica.xeniaeventi.it>, iscriversi al corso di riferimento e compilare:

- Il questionario di apprendimento online (doppia randomizzazione e nessuna possibilità di ripetizione) dalle ore 20:00 del 08/11/2024. L'ultimo giorno utile per la compilazione è il 12/11/2024 alle ore 23:59.
- La scheda di valutazione in formato anonimo.

Nella propria sezione è possibile scaricare l'attestato ECM. Il rilascio dei crediti ECM è subordinato all'attenta verifica della partecipazione (90% delle ore formative) e del questionario di valutazione (superato con almeno il 75% di risposte corrette).



RISE
MPN

Crediti ECM
10,0